Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 01, 2022, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Clarithromycin Tablets USP, 250 mg and 500 mg".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 01, 2022, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Clarithromycin Tablets USP, 250 mg and 500 mg".